GAITHERSBURG, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology, today announced the pricing of its upsized initial public offering of 6,471,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to NexImmune from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $110 million.
The shares are expected to begin trading on the Nasdaq Global Market on February 12, 2021 under the symbol “NEXI.” The offering is expected to close on February 17, 2021, subject to customary closing conditions.
LLS partnered with NexImmune in October 2017 through our Therapy Acceleration Program® (TAP) to support the preclinical and clinical development of novel T cell therapy programs, NEXI-001 and NEXI-002, in Phase 1/2 clinical trials for the treatment of relapsed AML after allo-HSCT and multiple myeloma refractory to at least three prior lines of therapy.